ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
A cerebrospinal fluid blood-brain barrier dysfunction score is associated with progression from mild cognitive impairment to Alzheimer's disease.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood-brain barrier permeability-related alterations are increasingly recognised as an early process in Alzheimer's disease, but their prognostic value and candidate molecular markers remain unclear.
methodsUsing longitudinal data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), we derived a cerebrospinal fluid BBB permeability-related score and evaluated its association with progression from mild cognitive impairment (MCI) to clinically diagnosed Alzheimer's disease dementia using Kaplan-Meier and multivariable Cox analyses. We additionally performed two-sample Mendelian randomisation screening across 832 CSF proteins in FinnGen, with replication in Bellenguez et al. 2022.
resultsAmong 134 MCI participants, the higher BBB permeability-related score group showed significantly faster progression to clinically diagnosed AD dementia (HR 1.73, 95% CI 1.10-2.74; p = 0.018), remaining significant after adjustment for CSF amyloid-beta, total-tau, and phosphorylated tau. CD226 (IVW OR 3.12; FDR = 0.018) and GFRα-1 (IVW OR 0.52; FDR = 0.009) were identified; CD226 showed directional consistency across datasets whereas GFRα-1 did not.
conclusionsA BBB permeability-related score is associated with longitudinal progression from MCI to clinically diagnosed AD dementia. CD226 is a biologically supported candidate signal; GFRα-1 is hypothesis-generating pending replication.
Indexed as
Identifiers
42635841What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.